1 / 18

Roger Prichard and Catherine Bourguinat Institute of Parasitology

Opportunities and challenges for mass chemotherapy programs against parasitic diseases in low-resource settings. Roger Prichard and Catherine Bourguinat Institute of Parasitology Centre for Host-Parasite Interactions McGill University Sainte Anne-de-Bellevue, Québec. Focus of presentation:.

louellad
Download Presentation

Roger Prichard and Catherine Bourguinat Institute of Parasitology

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Opportunities and challenges for mass chemotherapy programs against parasitic diseases in low-resource settings Roger Prichard and Catherine Bourguinat Institute of Parasitology Centre for Host-Parasite Interactions McGill University Sainte Anne-de-Bellevue, Québec

  2. Focus of presentation: • Diseases caused by helminth parasites • The burden of disease; diseases of poverty • Mass treatment programs • New opportunities • Donations • CDT • Integration of programs • Challenges • Compliance, sustainability, resources, donor fatigue • Treatment outcomes • Drug resistance; monitoring efficacy & impact

  3. The diseases • Lymphatic filariasis • Onchocerciasis • Soil transmitted helminths • Schistosomiasis

  4. Burden of high prevalence NTDs (modified from Hotez et al. Lancet 2009)

  5. Lymphatic Filariasis -1.2 billion people in 83 countries at risk -120 million people infected worldwide -India, Indonesia, Nigeria and Bangladesh (account for 70 % of global lymphatic filariasis infections) -Estimates of annual economic loss in India due to lymphatic filariasis - US $1b -Lymphoedema, hydrocele, elephantiasis, impaired motility, social stigma

  6. Soil-transmitted helminths The causal agent of soil-transmitted helminthiasis is any of the following worms: -Ascaris lumbricoidesImpair children’s growth, cognitive development, physical fitness -Trichuris trichiuraRectal prolapse,impair children’s growth, cognitive development, physical fitness - Hookworms (N. americanus, A. duodenale) Anemia in children and pregnant women, impair children’s growth, cognitive development, physical fitness STHs affects more than 2,000 million people worldwide -Globally STHs cause 3 – 24 m DALYs per year -STH infections predominantly in sub-Saharan Africa, the Americas, east and south Asia

  7. Onchocerciasis- River Blindness -Onchocerciasis –blindness, visual impairment, severe skin pathology - greatly reduces income-generating capacity, incurs significant health expenditures, reduces life expectancy and exerts a very negative socioeconomic impact on the afflicted populations and land use -Currently, via APOC/OEPA, more than 40 million people receive regular ivermectin treatment through a community drug-distribution Distribution of Onchocerciasis/Current Status of Global Onchocerciasis Control ▀APOC/OEPA IVM distribution ▀ Former OCP, now National IVM distribution ▀ IVM + vector control ▀ Epidemiological surveys required

  8. Schistosomiasis • - 200 million people infected; half in Africa (650 million people live in endemic areas) • 2nd most socioeconomically devastating parasitic disease, after malaria • Anemia, malnutrition, impaired cognitive development, damage to liver, intestines, lungs, bladder (bladder cancer), hepatosplenomegaly • Found in 74 tropical countries. • 3 main species of Schistosome in humans – • The drug praziquantel costs 18 cents per dose • >423 million tablets PZQ needed globally/year to treat schistosomiasis S. japonicum S. mansoni S. haematobium

  9. Lymphatic filariasis:Treatment and control • MDA (national programs + Internat. coord. - GPELF) with ABZ + DEC or ABZ + IVM to reduce transmission & arrest disease progression. Drugs not curative • Coupled with topical sanitation for secondary bacteria & fungi • ABZ donated by GSK (~180m doses/yr; Σ>1 b doses donated) • IVM (Mectizan) donated by Merck (>450 m doses donated) • DEC very inexpensive • Compliance & ineligible people • ABZ and IVM have collateral benefits of helping control STH • Transmission by mosquitoes: impregnated bed nets & insecticide spraying of houses for malaria control can reduce LF transmission • BMGF & others supporting LF ‘elimination’ programs

  10. HEALTH IMPACT: ‘BEYOND LF’ BENEFITS − Treatment of STH infections through national LF programs o >170 m treatments for STH (ABZ) given to 56 million children by GPELF, resulting in: 􀂃 Increased appetite, weight gain and growth 􀂃 Greater eye‐hand coordination, learning ability and concentration 􀂃 Better school attendance, cognitition, fitness scores & spontaneous play activity o >140 m treatments for STH (ABZ) given to 44.5 million women of childbearing age by GPELF, improving nutritional status & iron stores, leading to: 􀂃 Increased infant birth‐weights by up to 50 grams 􀂃 Decreased infant mortality by up to 40% & decreased maternal mortality

  11. HEALTH IMPACT: ‘BEYOND LF’ BENEFITS • Treatment of STH infections through national LF programs • >170 m treatments for STH (ABZ) given to 56 million children by GPELF, resulting in: • Increased appetite, weight gain and growth • Greater eye‐hand coordination, learning ability and concentration • Better school attendance, cognitition, fitness scores & spontaneous play activity • >140 m treatments for STH (ABZ) given to 44.5 million women of childbearing age by GPELF, improving nutritional status & iron stores, leading to: • Increased infant birth‐weights by up to 50 grams • Decreased infant mortality by up to 40% & decreased maternal mortality

  12. HEALTH IMPACT: ‘BEYOND LF’ BENEFITS • Treatment of onchocerciasis, scabies, and lice with IVM through the GPELF in Africa • >149 million IVM treatments given by GPELF, coordination with APOC to >45 million in African communities • Millions of people living in onchocerciasis‐endemic areas not previously treated, received IVM through coordination between GPELF and APOC • IVM’s long‐lasting impact on scabies reduces community prevalence after 1 cycle and almost eliminates it after >2 treatments: • Improved sleep patterns and overall well-being • Protection from post‐streptococcal renal disease induced by group B streptococcus skin infections that often complicate chronic scabies infection

  13. STH: Treatment & control • MDA programs(Deworm the World – Clinton Initiative; FRESH – World Bank; etc.) • Mainly BZ drugs – ABZ (best) or MBZ • ABZ being donated by GSK for LF control (not specifically for STH) • MBZ being donated by Johnson & Johnson • Efficacy ABZ (less for MBZ & other anthelmintics) • ~ 98% - Ascaris lumbricoides • ~ 50 – 70% Hookworms • ~ 30 – 50% Trichuris trichiura • Sometimes efficacy failure against hookworms & Trichuris. BZ resistance mutations recently found in N. americanus & T. trichiura • Need to monitor for drug resistance

  14. Onchocerciasis: Treatment & control • MDA by Community Directed Treatment (CDTI) • Compliance for CDTI variable • Only IVM (Mectizan) available for MDA • IVM donated by Merck (>600 m doses donated so far) • IVM kills microfilaria (mf) and inhibits production of new mf by adult worms for 3-12 months • IVM reduces morbidity & transmission (mf) • Does not kill adult worms • Oncho as public health problem markedly reduced • 20 years of IVM distribution in W. Africa • Transmission reduced but continues • IVM resistance now seen in West Africa • Difficult to monitor efficacy/resistance • SAE occasionally with heavy Loa loa co-infection

  15. Schistosomiasis: Treatment & control • National MDA, particularly of school children • Praziquantel: must be purchased ~ US $0.18/dose • Effectively no other drug now available • PZQ effective against adult parasites, not very effective against juvenile stages • Little immunity – reinfection • Some PZQ resistance reports – not widespread • Compliance & lack of resources problems • Snail vector control sometimes attempted

  16. General opportunities for NTD • Can use MDA including CDT • Drugs donated or cheap to buy • Donors willing to help • MDA - major impact on morbidity • Spectacular benefit/cost ratios (World Bank calculated intervention against NTD gave greatest returns on investments in development, compared with all other investments) • Possible to integrate all of these MDA interventions with others for Trachoma, malaria, etc.

  17. Challenges • Compliance & ineligible populations (e.g. pregnant women) • Lack of resources (shadow of big 3 - HIV/Malaria/TB) • ~ Drugs give ~ poor efficacy • MDA not curative – how many years MDA - sustainability? • Donor fatigue (donors want quick & easy fixes) • SAE with IVM in heavy L. loa infections • Developing drug resistance in: • O. volvulus • N. americanus & T. trichiura • Potentially in LF & S. mansoni • V. few drugs no development pipeline • Limited research funds & trained personnel

  18. Conclusions: • Control of these helminthic NTD - huge returns on investment in terms of human health and development, reduced suffering & social impacts • Huge numbers of people affected • Current tools for control are inadequate • Compliance/sustainability problems • Resistance developing to too few drugs • Control of NTDs appeals to donors; but • Donor fatigue & lack of realism • Lack of resources in endemic countries • Lack of research, drug pipeline, efficacy monitoring & trained personnel

More Related